Nationwide Population Based Seroprevalence Study of SARS-COVID-19 – Spain

Jul 20, 2020COVID Literature Appraisal, Epidemiology

Spain is one of the European countries most severely affected by the ongoing COVID-19 pandemic with about 30,000 deaths to-date. In infectious diseases with large number of asymptomatic cases, serological surveys are the best tool to estimate community spread of the disease, and development of herd immunity. In-spite of widespread infection the very low seroprevalence in Spain is worrying for all of us. Another seroprevalence study done at 10 sites in the USA till early May (JAMA Intern Med online 21 July 2020, doi: 10.1001/jamainternmed.2020.4130) too has shown similar low antibody prevalence rates ranging from 1% in the San Francisco Bay area to 6.9% in New York. If confirmed subsequently in other population groups as well, it implies that not only are the chances of natural immunity bleak, chances of a successful vaccination programme are also not too bright. Public health measures to prevent spread of infection in the community need to be continued earnestly and may be our only hope to contain the spread of COVID-19 in the immediate future

Article: Pallan M, Gómez BP, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet published online July 6, 2020. doi: 10.1016/S0140-6736(20)31483-5

Epidemiology-Seroprevalence in Spain_Revised